Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech firesales -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (574)	11/4/2003 9:57:17 AM
From: scaram(o)uche	Respond to of 3661

Bad, very, very bad. Go to the corner.

To: Biomaven who wrote (574)	11/4/2003 9:57:28 AM
From: nigel bates	Read Replies (1) \| Respond to of 3661

Or lack of taste issues ? HEPH down 20% or so on '2200 failure.

To: Biomaven who wrote (574)	11/4/2003 10:00:18 AM
From: tuck	Respond to of 3661

Hollis-Eden off ~25% on failure of dyslipidemia compound: >>SAN DIEGO--(BUSINESS WIRE)--Nov. 4, 2003-- Hollis-Eden Pharmaceuticals (Nasdaq:HEPH - News) today announced preliminary results of an exploratory Phase II clinical trial with the Company's investigational immune regulating hormone, HE2200, in patients with significant dyslipidemia that could not be corrected by strict dietary control. The study was designed to evaluate the safety of HE2200 as well as the effect of the compound when given buccally once daily for 28 days on a number of lipid parameters. Results of the study indicated that HE2200 was generally well tolerated. When compared to placebo, the compound did not have a statistically significant effect on lipids in the patient population overall in this trial. "This study, in which a total of 66 patients completed the trial, was designed based on findings from two earlier 30-person placebo controlled Phase I studies which showed that HE2200 reduced cholesterol levels after 3 days of subcutaneous or 5 days of buccal dosing in healthy volunteers who were not subject to strict dietary control," stated Dr. James Frincke, Chief Scientific Officer of Hollis-Eden. "While the preliminary results from this exploratory trial in patients with multiple lipid abnormalities do not confirm our earlier cholesterol findings, we continue to believe that this class of compounds has an important potential role to play in metabolic disorders. We are continuing to evaluate the data from this study as well as from preclinical work in this area. We will also be analyzing results from a separate Phase II clinical trial with HE2200 focused on immune enhancement in the elderly, which should be available in the next several months." "While we will continue to review further analyses and opportunities for HE2200, our top near-term priority clearly remains in the area of radiation and chemotherapy-induced immune suppression with HE2100," stated Richard Hollis, Chairman and CEO of Hollis-Eden. "We are making significant progress in these areas and I am pleased to announce today that we have been selected to give an oral presentation at the upcoming American Society of Hematology meeting that is taking place in San Diego December 6-9, 2003, where we will be presenting an update on these programs. We continue to move aggressively to bring HE2100 forward towards commercialization." << snip Cheers, Tuck